Global Health Limited Just Missed EPS By 8.2%: Here's What Analysts Think Will Happen Next

It's been a good week for Global Health Limited (NSE:MEDANTA) shareholders, because the company has just released its latest yearly results, and the shares gained 2.6% to ₹1,201. Revenues of ₹38b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at ₹17.92, missing estimates by 8.2%. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Global Health after the latest results.

We check all companies for important risks. See what we found for Global Health in our free report.

Taking into account the latest results, the most recent consensus for Global Health from 15 analysts is for revenues of ₹43.6b in 2026. If met, it would imply a decent 16% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to leap 32% to ₹23.68. In the lead-up to this report, the analysts had been modelling revenues of ₹43.5b and earnings per share (EPS) of ₹23.57 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Global Health

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹1,277. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Global Health, with the most bullish analyst valuing it at ₹1,465 and the most bearish at ₹855 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 16% growth on an annualised basis. That is in line with its 18% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 18% annually. So although Global Health is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at ₹1,277, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Global Health analysts - going out to 2028, and you can see them free on our platform here.

We also provide an overview of the Global Health Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.